Goldline Pharmaceutical IPO Day 2: GMP ₹17 (+₹2)
Welcome back, investors! It’s the second day of the Goldline Pharmaceutical SME IPO on the BSE, and we’ve got the latest subscription figures and Grey Market Premium (GMP) updates for you. As of today, May 13th, 2026, Goldline Pharmaceutical’s IPO, which opened yesterday for subscription and closes on May 14th, is showing some interesting early trends. The issue price is set at ₹41 per share, and the lot size is 3000 shares. Let’s dive into what the numbers are telling us.
| Date | GMP | Est. Listing |
|---|---|---|
| 18 May | +₹17 | ₹60 |
| 16 May | +₹17 | ₹60 |
| 15 May | +₹17 | ₹60 |
| 14 May | +₹25 | ₹68 |
| 13 May | +₹17 | ₹60 |
Subscription Status
As of Day 2, the subscription numbers for Goldline Pharmaceutical IPO are currently standing at 0x across all categories: Retail, Non-Institutional Investors (NII), and Qualified Institutional Buyers (QIB), with a total subscription of 0x. Now, before you get too concerned, it’s important to remember that this is an SME IPO, and often, the bulk of the subscriptions come in on the final day. So, while these numbers might seem unexciting right now, it’s not necessarily a red flag this early in the game. We’re seeing absolutely no applications yet, which is quite unusual even for an SME, but it’s still too early to draw definitive conclusions. Typically, retail investors tend to jump in towards the end, and NIIs and QIBs often wait for a clearer picture or make their move on the last day. The absence of any subscription at this stage could indicate a wait-and-watch approach from potential investors, or perhaps the marketing efforts are yet to gain full traction.
| Category | Subscription | Progress |
|---|---|---|
| Retail | 881.15x | |
| NII / HNI | 1,662.39x | |
| QIB | 180.22x | |
| Total | 840.81x |
| Date | Retail | NII | QIB | Total |
|---|---|---|---|---|
| 14 May | 881.15x | 1,662.39x | 180.22x | 840.81x |
| 13 May | 139.51x | 146.48x | 1.31x | 100.21x |
| 12 May | 34.07x | 24.46x | 1.31x | 22.35x |
GMP Update
Interestingly, the Grey Market Premium (GMP) for Goldline Pharmaceutical IPO is showing positive momentum. Yesterday, the GMP was at ₹15, but today, it has seen an increase of ₹2, standing at ₹17. This upward movement in GMP is a good sign. It suggests that the market sentiment towards Goldline Pharmaceutical is improving, and demand in the unofficial market is strengthening. Based on the issue price of ₹41 and the current GMP of ₹17, the expected listing price is around ₹58 (₹41 + ₹17). This projected listing price offers a decent potential upside for investors who manage to get an allotment. The rise in GMP, even with zero subscription numbers, indicates that some market participants are already anticipating a strong debut.
Should You Apply?
So, the million-dollar question: should you be applying for the Goldline Pharmaceutical IPO? We’ve got a situation here with zero subscriptions but a rising GMP. This is a classic scenario in the SME IPO market where GMP often leads the subscription numbers. The increased GMP to ₹17 is definitely encouraging, pointing towards a potential listing gain. However, the complete lack of subscription across all categories on Day 2 is something to ponder. It could be that investors are waiting for the final day’s rush, or it might be a sign of cautious sentiment. As SEBI advisors often highlight, it’s crucial to do your own research into the company’s fundamentals, financials, and future prospects. While GMP can be a good indicator of market sentiment, it’s not a guarantee. The bottom line is, if you’re comfortable with the risk associated with SME IPOs and the potential for listing gains, and you believe in Goldline Pharmaceutical’s business model, the current GMP might make it an attractive proposition. But remember, always invest with a clear understanding of the risks involved.